MHRA extends Cosentyx licence for paediatric arthritis
Data demonstrates that secukinumab shows a significantly longer time to flare versus placebo
Read More
Tag: Cosentyx
EU approves Norvatis’ Cosentyx for childhood arthritis
Cosentyx receives expanded approvals in EU for use in childhood arthritic conditions
Read More
Novartis’ Cosentyx wins NICE backing for non-radiographic axial spondyloarthritis
Axial spondyloarthritis affects approximately one in 200 people in the UK
Read More
Cosentyx approved to treat plaque psoriasis in paediatric patients
IL-17A inhibitor has been cleared in the US to treat plaque psoriasis in certain patients aged six years and older
Read More
Cosentyx gains EU approval for new label extension
Label update includes data for axial manifestations of psoriatic arthritis
Read More
Novartis’ Cosentyx reduces synovitis in new psoriatic arthritis study
Synovitis (joint lining inflammation) can lead to joint damage in psoriatic arthritis patients
Read More
Tremfya tops Cosentyx in late-stage study
The study is the first to compare Tremfya and the IL-17 inhibitor, Cosentyx.
Read More
Cosentyx successful in plaque psoriasis trial
The drug successfully modulates gene expression, leading to substantial improvement of inflammation.
Read More
Cosentyx demand helps drive Novartis’ net sales up 5% in 2018
Novartis has announced a rise of 5% in net sales in 2018, bringing the net total to $51.9 billion.
Read More
Plaque psoriasis study claims Tremfya superior to Cosentyx
Janssen’s plaque psoriasis treatment Tremfya was found to be superior to Novartis’ Cosentyx in treating adults with moderate-to-severe cases of the condition, according to findings of a late-stage study.
Read More
US approves joint damage data for Cosentyx
US regulators have approved new evidence showing that Novartis’ Cosentyx significantly slows progression of joint structural damage in patients with active psoriatic arthritis (PsA).
Read More
Novartis’ Cosentyx beats J&J’s Stelara in psoriasis trial
Novartis has released trial data showing that Cosentyx was “significantly more effective” than Johnson & Johnson’s rival biologic Stelara in achieving clear skin in patients with psoriasis.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
